Axsome Doses First Pediatric ADHD Patient in Phase III Solriamfetol Study

What happened

Axsome Therapeutics has initiated the Phase III FOCUS-2 study of solriamfetol for ADHD in children aged 6 to under 12, dosing the first patient on July 8, 2026. This trial expands the solriamfetol pipeline beyond its approved Sunosi label for excessive daytime sleepiness, following prior mixed results in adult ADHD and depression. The DeepValue report flags that the stock at ~$188 already prices in continued >30% revenue CAGR and successful near-term catalysts, leaving asymmetric downside if pipeline or commercial execution falters. While the pediatric ADHD program adds optionality, it is early-stage and does not alter the thesis that further multiple expansion is constrained by crowded bullish positioning. The risk-reward skew remains toward trimming on strength, with an attractive entry near $150.

Implication

For investors, the FOCUS-2 study is a positive but distant catalyst, with results years away and commercial viability uncertain given solriamfetol's prior regulatory setbacks in adult ADHD and depression. The DeepValue report's 'POTENTIAL SELL' rating reflects that consensus already prices in success across multiple programs, leaving little room for error. The trial does not alleviate concerns about Auvelity growth deceleration, balance sheet constraints, or the April 2026 AXS-05 PDUFA, where a narrow label could disappoint. Near-term, the crowded bullish sentiment and late-stage technical patterns argue for caution, with a trim above $210 and re-entry only after a pullback toward $150 or after post-PDUFA clarity. Long-term holders should monitor this trial for differentiation in a competitive ADHD market, but it provides no immediate margin of safety.

Thesis delta

The FOCUS-2 initiation adds a long-duration pipeline asset that strengthens the diversified CNS platform narrative, but it does not alter the core thesis that near-term risk-reward is unfavorable at current prices. The trial is too early to impact valuation and does not offset the downside risks from Auvelity growth slowdown or AXS-05 label limitations over the next 6–12 months.